CRBU (Caribou Biosciences) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRBU Caribou Biosciences Inc CRBU
65 GF Score
Price $1.49
GF Value $1.67
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences FFO per Share?

FFO per Share only applies to REITs.

CRBU
65GF Score
Caribou Biosciences Inc CRBU
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued. The current stock price of $1.49 is trading 10.8% below its estimated GF Value™ of $1.67. GuruFocus considers Caribou Biosciences to be Modestly Undervalued.

Key valuation signals for CRBU:

  • FFO per Share:
  • GF Value™: $1.67 vs. price of $1.49 (10.8% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
65GF Score

Get the complete analysis for CRBU

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price
$1.67
GF Value